title: National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
abstract: The National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation was organized and convened to identify, prioritize, and coordinate future research activities related to relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Each of the Workshop's 6 Working Committees has published individual reports of ongoing basic, translational, and clinical research and recommended areas for future research related to the areas of relapse biology, epidemiology, prevention, and treatment. This document summarizes each committee's recommendations and suggests 3 major initiatives for a coordinated research effort to address the problem of relapse after allo-HSCT: (1) to establish multicenter correlative and clinical trial networks for basic/translational, epidemiologic, and clinical research; (2) to establish a network of biorepositories for the collection of samples before and after allo-HSCT to aid in laboratory and clinical studies; and (3) to further refine, implement, and study the Workshop-proposed definitions for disease-specific response and relapse and recommendations for monitoring of minimal residual disease. These recommendations, in coordination with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly and efficiently address the significant problem of relapse after allo-HSCT.
authors.affiliation: Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA. mbishop@mail.nih.gov
authors.forename: Michael R
authors.initials: MR
authors.lastname: Bishop
authors.forename: Edwin P
authors.initials: EP
authors.lastname: Alyea
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
authors.forename: J H Frederik
authors.initials: JH
authors.lastname: Falkenburg
authors.forename: Carl H
authors.initials: CH
authors.lastname: June
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kröger
authors.forename: Richard F
authors.initials: RF
authors.lastname: Little
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Miller
authors.forename: Steven Z
authors.initials: SZ
authors.lastname: Pavletic
authors.forename: David L
authors.initials: DL
authors.lastname: Porter
authors.forename: Stanley R
authors.initials: SR
authors.lastname: Riddell
authors.forename: Koen
authors.initials: K
authors.lastname: van Besien
authors.forename: Alan S
authors.initials: AS
authors.lastname: Wayne
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Weisdorf
authors.forename: Roy S
authors.initials: RS
authors.lastname: Wu
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
mesh_terms: D002986:Clinical Trials as Topic; D004493:Education; D019337:Hematologic Neoplasms / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods*; D015337:Multicenter Studies as Topic; D054547:National Cancer Institute (U.S.); D018365:Neoplasm, Residual; D017410:Practice Guidelines as Topic; D012008:Recurrence; D014184:Transplantation, Homologous; D014481:United States